key: cord-0871256-mxqqh83f
authors: Borkotoky, Subhomoi; Banerjee, Manidipa; Prakash Modi, Gyan; Kumar Dubey, Vikash
title: Identification of high affinity and low molecular alternatives of boceprevir against SARS-CoV-2 main protease: a virtual screening approach
date: 2021-02-19
journal: Chem Phys Lett
DOI: 10.1016/j.cplett.2021.138446
sha: bc3d9421217b3bdd321c190d99a8056c909788db
doc_id: 871256
cord_uid: mxqqh83f

SARS-CoV-2 has posed global challenge for healthcare due to COVID-19. The main protease (Mpro) of this virus is considered as a major target for drug development efforts. In this work, we have used virtual screening approach with molecular dynamics simulations to identify high affinity and low molecular alternatives of boceprevir, a repurposed drug currently being evaluated against Mpro. Out of 180 compounds screened, two boceprevir analogs (PubChem ID: 57841991 and 58606278) were reported as potential alternatives with comparable predicted protease inhibitor potential and pharmacological properties. Further experimental validation of the reported compounds may contribute to the ongoing investigation of boceprevir.

As the world keeps on battling the COVID-19 pandemic, worldwide endeavors are progressing for the rapid identification of effective vaccines as well as antivirals. At present there are 63 vaccines under clinical trials (https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines). Antivirals such as Ivermectin and Danoprevir (clinical trial ID: NCT04435587 and NCT04291729 respectively) are under phase IV of clinical trial among others. Albeit multiple vaccines and inhibitors have entered clinical trials, endeavors to develop inhibitors and antibodies are as yet critical to treat this disease on account of clinical need and mutations in the virus that could influence the efficacy of the antiviral agents [1, 2] .

The single stranded positive-sense RNA genome of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) comprises of ~30,000 nucleotides [3, 4] . The replicase gene of the virus, encompassing more than 21,000 nucleotides, encodes two overlapping polyproteins, pp1a (~ 486 kDa) and pp1ab (~ 790 kDa). These polyproteins are essential for the replication and transcription of coronaviruses. The main protease, a 33.8-kDa cysteine protease, and papain-like protease (PL pro ) are essential for proteolytic processing of these polyproteins into functional peptides in a multistep process [5, 6] . As a drug target, PL pro is not so much preferred as it recognizes the C-terminal sequence of ubiquitin, and compounds inhibiting PL pro may also inhibit host cell deubiquitinases. However, the M pro cleaves at a very specific cleave site of the polypeptide sequences and prefers a glutamine residue at the P1 site. The cleavage site of M pro is [Leu-Gln↓ (Ser, Ala, Gly)] (↓: cleavage site). Such cleavage specificity is not reported in any human proteases [7, 8] . These functional attributes make M pro an attractive target for drug development studies. The determination of multiple experimental structures of M pro in its apo form and with co-crystallized ligands dramatically facilitates the process of drug discovery. The usual drug development process typically costs a lot of time and money. Hence, multiple efforts are going on for computational screening of large chemical libraries as well as re-purposing antivirals for the rapid identification of lead compounds with the potential to be translated into effective and safe drugs.

The main protease (M pro ) from SARS-CoV-2 shows structural similarity with other main proteases and has three domains. The two domains, domains I (residues 8-101) and II (residues 102-184) have mainly antiparallel β-barrel structures while domain III covering amino acid residues 201-303 contain five α-helices [6, 9] [10] .

Boceprevir (M.W.: 519.68 g/mol,) is an FDA approved drug against hepatitis C virus (HCV) that targets serine protease NS3 for inhibitor. It is reported to be well tolerated with few drug-drug interactions, and no major hepatic or renal toxicity [11] . A recent report suggests that boceprevir inhibits the enzymatic activity of M pro with an IC 50 value of 4.13 µM [12] . The cellular cytotoxicity testing was also found to be well tolerated with a CC 50 value of over 100 µM for all the cell lines tested. The same study also reported that boceprevir has potent antiviral activity against SARS-CoV-2. The crystal structure of M pro complexed with boceprevir (PDB ID: 6WNP) also shows that it effectively binds to the catalytic residues.

Since boceprevir is a promising candidate to be an effective drug, we have used virtual screening in combination with molecular dynamics (MD) simulations to find a possible candidate with better binding from a library of compounds similar to boceprevir. Among the 180 low molecular weight boceprevir analogs, two compounds (PubChem ID: 57841991 and 58606278) formed stronger and stable interactions to the binding site than boceprevir. We hope this study will aid the rapid discovery of inhibitors against M pro with more efficiency.

Out of 1,275 similar compounds of boceprevir available in PubChem database [13] , we retrieved a total of 180 compounds having molecular weight less than 519.68 g/mol with available 3D conformers. Compounds having a Tanimoto score of 0.9 or greater were considered as similar compounds based on 2D similarity [14] . The M pro structure at room temperature (PDB ID: 6WQF) [9] was selected for docking since it had the suggested protonation states of histidine residues, and the structure was solved at room temperature. It has been suggested that this structure solved at room temperature is more appropriate for molecular docking studies as it provides more relevant information at physiological temperatures [9] . The compounds were energy minimized with the steepest descent algorithm prior to docking using UCSF Chimera [15] . The selected compounds, along with boceprevir as control were docked by centering the grid box centered on the substrate-binding site of M pro (x, y and z center coordinates :36.56, 46.43 and 56.04) with the AutoDock vina program [16] . The screening was performed with a exhaustiveness value of 8 and ten runs for each compound, and the best pose was selected based on the lowest binding free energy (kcal/mol). The 2D ligand interactions were visualized with the Discovery studio visualizer [17] .

The PASS (Prediction of Activity Spectra for Substances) server (http://www.pharmaexpert.ru/passonline/) [18] was utilized to predict the protease inhibition probability of the selected compounds. The server can predict pharmacological effects and biochemical mechanisms of a compound based on the structural formula and the prediction may be analyzed based on the ratio of probability to be active (Pa) and probability to be inactive (Pi).

were calculated based on human intestinal absorption (HIA), blood-brain barrier permeability, CYP2D6 inhibitor/substrate, and Ames mutagenicity and mouse carcinogenicity parameters respectively. The excretion parameter is represented by HIA, as it is a sum of bioavailability and absorption evaluated from the ratio of excretion or cumulative excretion in urine, bile, and feces [19] . The pharmacokinetic parameters were predicted by using the pre-ADMET server (https://preadmet.bmdrc.kr/) [20] .

MD Simulation is a routinely applied method to decipher the dynamic interactions between biomolecules with small molecules, peptides, or nanoparticles [21] [22] [23] [24] . For exploring the binding dynamics, the apo-protein, and docked complexes were simulated using GROMACS v.2018 with the GROMOS 54a7 force field [25] . PRODRG server was used to calculate the ligand parameters [26] . The catalytic dyad is suggested to be activated by a proton transfer from Cys 145 to His 41 possibly activated by substrate binding [9] . Therefore, the His 41 and Cys 145 were prepared in their neutral state, with His41 protonated at Nδ. Based on previous studies protonation states of other histidine residues were assigned at the Nδ (HISA) or Nε (HISB) sites as follows: HISA64, HISA80, HISB163, HISB164, HISB172, and HISB246 [27, 28] . The system was solvated in a cubic box of 1.2 nm containing SPC water molecules. The addition of NA + ions neutralized the charge of the systems. The steepest descent method was utilized for energy minimization for 50,000 steps for all systems with a tolerance of 1000 kJ mol -1 nm -1 . NVT and NPT equilibrations were carried out at 300 K and 1 bar using the V-rescale thermostat and Berendsen barostat [9] . The final production of 130 ns was performed using the leap-frog integration with Nose-Hoover and Parinello-Rahman couplings [29] . Bond-lengths were constrained using the Linear Constraint Solver (LINCS) algorithm [30] . The trajectories were analyzed using GROMACS inbuilt utilities.

To estimate the post-simulation binding free energy of the complexes, the molecular mechanics Poisson-Boltzmann surface area (MM-PBSA) approach was utilized. This approach has been successfully applied to various protein-ligand/peptide complexes [31, 32] . The binding free energy, and per residue energy contributions were calculated using the g_mmpbsa tool [33] . This GROMACS tool estimates Gibb's free energy of binding using the MM-PBSA method as described by the equation below. The SASA model was used for calculation of nonpolar solvation energy in this study.

The g_mmpbsa tool also calculates the energy contribution of each residue by decomposing the total binding free energy at the residue level [33] .

The control compound boceprevir (PubChem ID: 10324367) scored -6.8 kcal/mol while docked with AutoDock vina. The top six compounds 58606278, 58605188, 59115738, 58908774, 58605473, and 57841991 were selected based on the binding energy ( Fig. 1 

The compounds were analyzed in the PASS prediction server to explore the possible protease inhibitor potential ( Table 2 ). The protease inhibitory activity of the compounds was compared demonstrated no CYP2D6 inhibitor/substrate potential, Ames mutagenicity and mouse carcinogenicity similar to boceprevir. Since 59115738 had a very low probability of being a protease inhibitor and was therefore excluded from further analysis.

The displayed the lowest RMSF among the simulated complexes followed by 58606278 and 58605473 complexes (Fig. 3b) . A similar pattern of RMSF was observed for the substratebinding region as well (Fig. 3c) binding residues for the 58605188 complex was found to highest among the complexes.

The interactions of the compounds with M pro were mapped by hydrogen bond (H-bond) graphs ( Fig. 4) . Boceprevir initially formed a maximum of 8 H-bonds but the number was reduced after 50 ns (Fig. 4a) . The compound 57841991 (Fig. 4b) formed higher H-bonds up to 10 and maintained overall 8 H-bonds from 20 ns. The compound 58605188 maintained 5 H-bonds consistently from 70 ns (Fig. 4c) while the compound 58605473 formed 4 H-bonds in most of the simulation period (Fig. 4d) . The compound 58606278 formed 6 H-bonds in a comparatively consistent way throughout the simulation period (Fig. 4e) . Among the complexes studied, 58908774 formed the lowest number of H-bonds which was found to 2 on average (Fig. 4f) .

These trends of interactions can be correlated with changes in the RMSF of the complexes. The higher RMSF values of the 58605188 and 58908774 complexes may lead to loss of interactions found during the docking calculations.

Based on the RMSD, RMSF, and H-bond interaction analysis, the complexes formed by the compounds 57841991, 58605473, and 58606278 were selected for MM-PBSA analysis along with boceprevir. Energy components of each complex were calculated for 101 snapshots that were extracted at every 0.1 ns from the final 10 ns. Among the complexes, 57841991 scored the highest binding free energy -14.32 kcal/mol, which is higher than the boceprevir complex (-5.83

kcal/mol). The other two complexes formed by 58605473 and 58606278 scored -9.01 and -6.48

kcal/mol respectively. In the case of the 57841991 complex the contributions of van der Waals, polar solvation energy, and SASA energy to the binding free energy were found to be higher among the complexes. The binding energy differences in the 58605473 and 58606278 complexes were contributed by the energy contributions from van der Waals, electrostatic energy, and polar solvation energy.

To evaluate the binding pattern, the strong energy contribution of the substrate-binding residues for these complexes were calculated (Fig. 5) . From the residue contribution analysis, it was observed that for 58605473 complex, there is more negative contribution of substrate binding residues on average (-0.16 kcal/mol). Whereas the average energy contribution of the residues in the complexes 57841991 and 58606278 were found to be more positively contributing -0.47 kcal/mol and -0.28 kcal/mol respectively, which is better than boceprevir complex (-0.24 kcal/mol). The energy contribution from the critical catalytic residues His 41 and Cys 145 were also found to be stronger in these two complexes, which were found to be contributing poorly in the 58605473 complex. Other highly contributing residues in the 57841991 complex are Met 165 , Asp 187 , Arg 188 , Gln 189 , and Thr 190 which were higher among the complexes.

Understanding protein structure is of fundamental importance [35] . Moreover, with the growing number of daily cases of COVID-19 infections, subsequent efforts to combat the disease are also rising. Apart from the efforts to the development of a successful vaccine candidate, there are also multiple computational and experimental efforts to identify effective drugs/inhibitors either by repurposing the existing drugs or designing novel compounds [36] [37] [38] [39] [40] . Multiple studies also proposed natural compounds as potential inhibitors of SARS CoV-2 main protease [41] [42] [43] [44] .

In this work, we have computationally investigated possible high affinity and low molecular In conclusion, the overall observations from this computational study suggest that the compounds 57841991 and 58606278 could be investigated as low molecular weight alternatives of boceprevir. Experimental validation and optimization of the reported compounds might contribute to the development of a more potent analog of boceprevir against SARS-CoV-2.

The authors declare that they have no conflict of interest.

The 

Other interactions Table 2 . Protease inhibitor potential along with ADMT properties of the selected compounds. 

On the origin and continuing evolution of SARS-CoV-2

Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease. Microorganisms

Genome evolution of SARS-CoV-2 and its virological characteristics

SARS coronavirus 2: from genome to infectome

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

The SARS-CoV-2 main protease as drug target

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Structural plasticity of SARS-CoV-2 3CL M(pro) active site cavity revealed by room temperature X-ray crystallography

Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy

Drugs Today (Barc)

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

PubChem Substance and Compound databases

Similar compounds versus similar conformers: complementarity between PubChem 2-D and 3-D neighboring sets

UCSF Chimera--a visualization system for exploratory research and analysis

AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading

Discovery studio visualizer

PASS: prediction of activity spectra for biologically active substances

Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors

The PreADME Approach: Web-based program for rapid prediction of physico-chemical, drug absorption and drug-like properties

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors

In silico identification and design of potent peptide inhibitors against PDZ-3 domain of Postsynaptic Density Protein (PSD-95)

Computational Analysis of the Silver Nanoparticle-Human Serum Albumin Complex

Singha Roy A: Exploring the interaction of bioactive kaempferol with serum albumin, lysozyme and hemoglobin: A biophysical investigation using multi-spectroscopic, docking and molecular dynamics simulation studies

Definition and testing of the GROMOS force-field versions 54A7 and 54B7

PRODRG: a tool for high-throughput crystallography of protein-ligand complexes

Supercomputer-Based Ensemble Docking Drug Discovery Pipeline with Application to Covid-19

Evidence for substrate binding-induced zwitterion formation in the catalytic Cys-His dyad of the SARS-CoV main protease

Predicting crystal structures: the Parrinello-Rahman method revisited. Physical review letters

LINCS: a linear constraint solver for molecular simulations

α-Glucosidase inhibitory effect of anthocyanins from Cinnamomum camphora fruit: Inhibition kinetics and mechanistic insights through in vitro and in silico studies

In vitro and MD simulation study to explore physicochemical parameters for antibacterial peptide to become potent anticancer peptide

g_mmpbsa--a GROMACS tool for high-throughput MM-PBSA calculations

Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease

A logical OR redundancy within the Asx-Pro-Asx-Gly type I β-turn motif

Impact of repurposed drugs on the symptomatic COVID-19 patients

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs

Computational drug repurposing for the identification of SARS-CoV-2 main protease inhibitors

Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro

High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase

Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic

Natural Compounds as Inhibitors of SARS-CoV-2 Main Protease (3CLpro): A Molecular Docking and Simulation Approach to Combat COVID-19

Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)

A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2

His 41* , Cys 44# , Ser 46#

Ser 46# , Met 49# , Phe 140# , Leu 141# , His 163# , Met 165* , Leu 167* , Pro 168* , Arg 188# , Gln 189# , Thr 190#

His 41*# , Cys 44# , Ser 46# , Met 49# , Phe 140# , Leu 141# , His 163* , Met 165* , Leu 167#

Thr 190# , Gln 192# 7 57841991 505.6 -7.2 NH(Gly

Akyl and $ carbon-hydrogen bond